

Prof. Alper OKYAR

Personal Information

Office Phone: [+90 212 440 0000](tel:+902124400000) Extension: 13449

Email: aokyar@istanbul.edu.tr

Web: <http://oubs.iu.edu.tr/akademik.php?268=>

Address: İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji AD Beyazıt-İstanbul

International Researcher IDs

ScholarID: x-Cxe1gAAAAJ

ORCID: 0000-0002-9891-5588

Publons / Web Of Science ResearcherID: AAD-3114-2020

ScopusID: 23106888700

Yoksis Researcher ID: 32898

Education Information

Doctorate, Istanbul University, Sağlık Bil. Ens., Farmakoloji Anabilim Dalı, Turkey 1997 - 2004

Postgraduate, Istanbul University, Sağlık Bil. Ens., Farmakoloji Anabilim Dalı, Turkey 1995 - 1997

Undergraduate, Istanbul University, Faculty Of Pharmacy , Turkey 1990 - 1994

Foreign Languages

English, B2 Upper Intermediate

Certificates, Courses and Trainings

Education Management and Planning, Deney Hayvanları Kullanım Kursu, İÜ Hayvan Deneyleri Yerel Etik Kurul Başkanlığı, 2011

Education Management and Planning, Klinik Araştırmalarda Etik Yaklaşım Kursu, TC Sağlık Bak. İlaç ve Eczacılık Genel Müd., 2009

Education Management and Planning, VIII. Uluslararası Kronofarmakoloji Kursu, Ruprecht-Karls Üniversitesi Heidelberg, 2007

Education Management and Planning, XII. Uygulamalı Flow Sitometri Eğitimi, İstanbul Üniversitesi Deneysel Tıp Araştırma Enstitüsü (DETAE), 2006

Dissertations

Doctorate, Vinblastin ve atorvastatinin P-glikoprotein üzerinden talinolol farmakokinetiğini değiştirmesinin incelenmesi , Istanbul University, Sağlık Bil. Ens., Farmakoloji Anabilim Dalı, 2004

Postgraduate, Setirizinin psikomotor performans etkisinin psikometrik testlerle incelenmesi , Istanbul University, Sağlık Bil. Ens., Farmakoloji Anabilim Dalı, 1997

Research Areas

Health Sciences, Pharmacology and Therapeutics, Professional Sciences, Pharmacology

Academic Titles / Tasks

Professor, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2018 - Continues

Associate Professor, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2012 - 2018

Assistant Professor, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2006 - 2014

Research Assistant PhD, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 2004 - 2006

Research Assistant, Istanbul University, Faculty of Pharmacy , Department of Professional Pharmaceutical Sciences, 1996 - 2006

Academic and Administrative Experience

Ethics Committee Member, Istanbul University, 2019 - Continues

İstanbul Üniversitesi, Teknoloji Transfer Uygulama Ve Araştırma Merkezi, 2019 - Continues

İstanbul Üniversitesi, İü Teknoloji Transfer Merkezi , 2015 - Continues

Rector's Advisor, Istanbul University, 2019 - 2023

Courses

Farmakoloji-I, Undergraduate, 2015 - 2016

Sempatik Sinir Sistemi Farmakolojisi, Doctorate, 2015 - 2016

Farmakoloji-III, Undergraduate, 2015 - 2016

Su Ürünlerinde Farmakoloji, Undergraduate, 2015 - 2016

İleri Farmakolojik Deney Teknikleri, Doctorate, 2015 - 2016

Nörofarmakoloji, Doctorate, 2014 - 2015

Otakoidler, Doctorate, 2014 - 2015

Farmakokinetik , Postgraduate, 2013 - 2014

Su Ürünlerinde Farmakoloji, Undergraduate, 2014 - 2015

Bilimsel Sunum teknikleri, Postgraduate, 2013 - 2014

Farmakoloji-II, Undergraduate, 2013 - 2014

Farmakoterapi-I, Undergraduate, 2013 - 2014

Klinik eczacılık, Undergraduate, 2013 - 2014

Farmakoloji-II, Undergraduate, 2013 - 2014

Advising Theses

OKYAR A., mTOR inhibitörü everolimusun faredeki kronofarmakokinetiği, Doctorate, D.Öztürk(Student), 2019

Okyar A., mTOR İnhibitörü Everolimusun Yaşa Bağlı Farmakinetiğinin İncelenmesi, Postgraduate, F.Öztürk(Student), 2019

OKYAR A., mTOR İNHİBİTÖRÜ EVEROLİMUSUN KRONOTOKSİSİTESİNİN FARELERDE İNCELENMESİ, Doctorate, N.Öztürk(Student), 2015

OKYAR A., P-glikoprotein substratı talinololün dişi ve erkek farelerdeki farmakokinetiği, Postgraduate, D.Öztürk(Student), 2014

OKYAR A., Barnidipin ve talinolol arasındaki P-glikoproteine bağlı olası bir farmakokinetik etkileşmenin incelenmesi, Postgraduate, N.Öztürk(Student), 2010

OKYAR A., Tiyapfenik asidin sıçan derisinden penetrasyonunun in vitro ve in vivo incelenmesi, Postgraduate, M.Nuriyev(Student), 2009

Jury Memberships

Doctorate, Tez Savunma Jürisi, Marmara Üniversitesi Tıp Fakültesi, October, 2017

Doctorate, Tez Savunma Jürisi, İstanbul Üniversitesi Eczacılık Fakültesi, June, 2015

Appointment to Academic Staff-Assistant Professorship, Yrd. Doç. Kadro Ataması, İstanbul Üniversitesi Eczacılık Fakültesi, April, 2015

Post Graduate, Tez Savunma Sınavı Jürisi, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, January, 2015

Doctoral Examination, Doktora Yeterlik Sınavı, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, June, 2014

Doctoral Examination, Doktora Yeterlik Sınavı, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, June, 2013

Post Graduate, Tez Savunma Sınavı Jürisi, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, April, 2013

Appointment to Academic Staff-Assistant Professorship, Yrd. Doç. Kadro Ataması, İstanbul Üniversitesi Eczacılık Fakültesi, May, 2012

Doctorate, Tez Savunma Sınavı Jürisi, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, July, 2010

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The effect of biocompatible carriers with vitamin D and platelet-rich plasma (PRP) on bone defects"**
Yaltrık M., Okyar A., Dirican A., Özsoy Y., Güngör S., Turgut C. T., Kotil T., Öztürk Civelek D.
HIPPOKRATIA, vol.27, no.2, pp.48-56, 2024 (SCI-Expanded)
- II. **Dosing-time, feeding, and sex-dependent variations of everolimus pharmacokinetics in mice.**
Ozturk Civelek D., Ozturk Seyhan N., Akyel Y. K., Gazioglu I., Pala Kara Z., Orman M. N., Okyar A.
Fundamental & clinical pharmacology, 2024 (SCI-Expanded)
- III. **Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy**
Lévi F. A., OKYAR A., Hadadi E., Innominato P. F., Ballesta A.
Annual review of pharmacology and toxicology, vol.64, pp.89-114, 2024 (SCI-Expanded)
- IV. **The role of the circadian timing system on drug metabolism and detoxification: an update**
OKYAR A., ÖZTÜRK CİVELEK D., AKYEL Y. K., Surme S., PALA KARA Z., Kavaklı İ. H.
Expert Opinion on Drug Metabolism and Toxicology, vol.20, no.6, pp.503-517, 2024 (SCI-Expanded)
- V. **TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice**
Surme S., Ergun C., Gul S., AKYEL Y. K., Gul Z. M., Ozcan O., Ipek O. S., Akarlar B. A., Ozlu N., TAŞKIN A. C., et al.
Biochemical Pharmacology, vol.218, 2023 (SCI-Expanded)
- VI. **Induction of humoral and cell-mediated immunity in mice by chitosan-curdlan composite nanoparticles administered intranasally and subcutaneously**
SESSEVMEZ M., Sinani G., OKYAR A., Alpar H. O., CEVHER E.
Journal of Drug Delivery Science and Technology, vol.86, 2023 (SCI-Expanded)
- VII. **Therapeutic Effect of C-Vx Substance in K18-hACE2 Transgenic Mice Infected with SARS-CoV-2**
Ulbeği Polat H., Abacı I., Tas Ekiz A., Aksoy O., ÖKTELİK F. B., YILMAZ V., Tekin S., OKYAR A., Oncul O., DENİZ G.
International Journal of Molecular Sciences, vol.24, no.15, 2023 (SCI-Expanded)
- VIII. **Circadian Dysfunction in Adipose Tissue: Chronotherapy in Metabolic Diseases**
CİVELEK E., ÖZTÜRK CİVELEK D., AKYEL Y. K., KALELİ DURMAN D., OKYAR A.
Biology, vol.12, no.8, 2023 (SCI-Expanded)

- IX. **Modulation of monepantel secretion into milk by soy isoflavones**
GÜNEŞ Y., Okyar A., Krajcsi P., Fekete Z., ÜSTÜNER O.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol.46, no.3, pp.185-194, 2023 (SCI-Expanded)
- X. **The effect of biocompatible carriers with vitamin D and platelet-rich plasma (PRP) on bone defects**
Yaltrık M., Okyar A., Erginer Y., Öztürk Civelek D., Kotil T., Dirican A., Güngör S., Turgut C. T.
HIPPOKRATIA, vol.27, no.2, pp.48-56, 2023 (SCI-Expanded)
- XI. **Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice**
Akyel Y. K., Ozturk Civelek D., Ozturk Seyhan N., Gul Ş., Gazioglu I., Pala Kara Z., Lévi F., Kavakli I. H., Okyar A.
JOURNAL OF BIOLOGICAL RHYTHMS, vol.38, no.2, pp.171-184, 2023 (SCI-Expanded)
- XII. **Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in *p53* knockout mice**
Gul Ş., Akyel Y. K., Gul Z. M., Isin S., Ozcan O., Korkmaz T., Selvi S., Danis I., Ipek O. S., Aygenli F., et al.
NATURE COMMUNICATIONS, vol.13, no.1, 2022 (SCI-Expanded)
- XIII. **Dosing-time dependent testicular toxicity of everolimus in mice**
Ozturk N., Civelek D. O., Sancar S., Kaptan E., Kara Z., Okyar A.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.165, 2021 (SCI-Expanded)
- XIV. **In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials**
Gul Ş., Ozcan O., Asar S., OKYAR A., Baris I., Kavakli I. H.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, vol.39, no.17, pp.6772-6791, 2021 (SCI-Expanded)
- XV. **The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice**
Pala K., Ozturk C., Ozturk N., Okyar A.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.156, 2021 (SCI-Expanded)
- XVI. **Reproductive effects of subchronic exposure to acetamiprid in male rats**
Arıcan E., Gökçeoğlu K., Ulus K., Boran T., Öztürk N., Okyar A., Ercan F., Özhan G.
SCIENTIFIC REPORTS, vol.10, no.1, 2020 (SCI-Expanded)
- XVII. **Effects of atorvastatin on talinolol absorption: A potential drug-drug interaction.**
Kara Z., Ozturk D., Ozturk N., Orman M., Baktir G., Okyar A.
Die Pharmazie, vol.75, pp.70-74, 2020 (SCI-Expanded)
- XVIII. **A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude.**
Doruk Y., Yarparvar D., Akyel Y., Gul Ş., Taskin A. C., Yilmaz F., Baris I., Ozturk N., Türkay M., Ozturk N., et al.
The Journal of biological chemistry, vol.295, no.11, pp.3518-3531, 2020 (SCI-Expanded)
- XIX. **Toxic effects of subchronic oral acetamiprid exposure in rats**
Karaca B. U., Arıcan Y. E., Boran T., Binay S., Okyar A., Kaptan E., Ozhan G.
TOXICOLOGY AND INDUSTRIAL HEALTH, vol.35, pp.679-687, 2019 (SCI-Expanded)
- XX. **Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.**
Okyar A., Kumar S. A., Filipski E., Piccolo E., Ozturk N., Xandri-Monje H., Pala Z., Abraham K., Gomes A. R. G. D. J., Orman M. N., et al.
Scientific reports, vol.9, pp.10505, 2019 (SCI-Expanded)
- XXI. **Gliclazide alone or in combination with atorvastatin ameliorated reproductive damage in streptozotocin-induced type 2 diabetic male rats**
Oztaş E., YILMAZ T. E., GUZEL E., SEZER Z., Okyar A., Ozhan G.
SAUDI PHARMACEUTICAL JOURNAL, vol.27, no.3, pp.422-431, 2019 (SCI-Expanded)
- XXII. **The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus**
Ozturk N., Öztürk D., Pala-Kara Z., Kaptan E., Sancar-Bas S., Ozsoy N., Cinar S., Deniz G., Li X., Giacchetti S., et al.
Chronobiology International, vol.35, pp.705-718, 2018 (SCI-Expanded)
- XXIII. **Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy**

- Ozturk N., Ozturk D., Kavakli I. H., Okyar A.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol.18, no.10, 2017 (SCI-Expanded)
- XXIV. **Nasal vaccination with poly(β -amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles.**
SINANI G., Sessevmez M., Koray G., Özgümüş S., Okyar A., Oya A., Cevher E.
International journal of pharmaceutics, vol.529, pp.1-14, 2017 (SCI-Expanded)
- XXV. **Critical cholangiocarcinogenesis control by cryptochrome clock genes**
Mteyrek A., Filipski E., GUETTIER C., OKLEJEWICZ M., VAN DER HORST G. T. J., Okyar A., Levi F.
INTERNATIONAL JOURNAL OF CANCER, vol.140, no.11, pp.2473-2483, 2017 (SCI-Expanded)
- XXVI. **Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation**
Ozturk N., Öztürk D., Pala-Kara Z., Okyar A.
PHARMAZIE, vol.72, no.1, pp.29-34, 2017 (SCI-Expanded)
- XXVII. **Clock gene Per2 as a controller of liver carcinogenesis**
Mteyrek A., Filipski E., GUETTIER C., Okyar A., Levi F.
ONCOTARGET, vol.7, no.52, pp.85832-85847, 2016 (SCI-Expanded)
- XXVIII. **Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study**
PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., Namal E., CIFTCI R., Iner-Koksal U., Kaytan-Saglam E.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.78, no.1, pp.143-150, 2016 (SCI-Expanded)
- XXIX. **Carbon tetrachloride-induced kidney damage and protective effect of *Amaranthus lividus* L. in rats**
Yilmaz-Ozden T., Can A., Karatug A., Pala-Kara Z., Okyar A., Bolkent S.
TOXICOLOGY AND INDUSTRIAL HEALTH, vol.32, no.6, pp.1143-1152, 2016 (SCI-Expanded)
- XXX. **Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy**
Dallmann R., Okyar A., Leyi F.
TRENDS IN MOLECULAR MEDICINE, vol.22, no.5, pp.430-445, 2016 (SCI-Expanded)
- XXXI. **THE PROTECTIVE EFFECT OF AN AQUEOUS EXTRACT FROM SMILAX EXCELSA L. AGAINST CARBON TETRACHLORIDE-INDUCED LIVER INJURY IN RATS**
Ozsoy N., Okyar A., Arda-Pirincci P., Can A., Bolkent Ş., Akev N.
AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES, vol.13, no.3, pp.203-208, 2016 (SCI-Expanded)
- XXXII. **Preparation and in-vivo evaluation of dimenhydrinate buccalmucoadhesive films with enhanced bioavailability**
Pekoz A., Erdal M. S., Okyar A., Ocak M., Tekeli F., Kaptan E., Sagirli O., Araman A.
Drug Development and Industrial Pharmacy, vol.42, no.6, pp.916-925, 2016 (SCI-Expanded)
- XXXIII. **Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling**
Dulong S., Ballesta A., Okyar A., Levi F.
MOLECULAR CANCER THERAPEUTICS, vol.14, no.9, pp.2154-2164, 2015 (SCI-Expanded)
- XXXIV. **Protective effect of *Amaranthus lividus* L. on carbon tetrachloride induced hepatotoxicity in rats**
Yilmaz-Ozden T., Can A., Sancar-Bas S., Pala-Kara Z., Okyar A., Bolkent Ş.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.40, no.2, pp.125-131, 2015 (SCI-Expanded)
- XXXV. **Carbon tetrachloride induced kidney damage and protective effect of *Amaranthus lividus* L. in rats**
YILMAZ ÖZDEN T., CAN A., KARATUĞ A., PALA KARA Z., OKYAR A., BOLKENT Ş.
TOXICOLOGY AND INDUSTRIAL HEALTH, pp.1-10, 2014 (SCI-Expanded)
- XXXVI. **Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study**
Akgun Z., Saglam S., YÜCEL S., Gural Z., Balik E., Cipe G., YILDIZ Ş., Kilickap S., Okyar A., Kaytan-Saglam E.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.74, no.4, pp.751-756, 2014 (SCI-Expanded)
- XXXVII. **Optimization of irinotecan chronotherapy with P-glycoprotein inhibition**
Filipski E., Berland E., Ozturk N., GUETTIER C., VAN DER HORST G. T. J., Levi F., Okyar A.
TOXICOLOGY AND APPLIED PHARMACOLOGY, vol.274, no.3, pp.471-479, 2014 (SCI-Expanded)

- XXXVIII. **Evaluation of Smilax excelsa L. Use in Experimentally Induced Nephrotoxicity**
 Ozsoy N., Okyar A., Arda-Pirincci P., Can A., Bolkent S., Akev N.
 KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI, vol.19, pp.807-814, 2013 (SCI-Expanded)
- XXXIX. **The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels**
 Benian A., Guralp O., Uzun D. D., Okyar A., Sahmay S.
 GYNECOLOGICAL ENDOCRINOLOGY, vol.29, no.3, pp.226-229, 2013 (SCI-Expanded)
- XL. **Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance**
 Okyar A., Dressler C., Hanafy A., Baktir G., Lemmer B., Spahn-Langguth H.
 CHRONOBIOLOGY INTERNATIONAL, vol.29, no.4, pp.443-453, 2012 (SCI-Expanded)
- XLI. **Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics**
 Levi F., Okyar A.
 EXPERT OPINION ON DRUG DELIVERY, vol.8, no.12, pp.1535-1541, 2011 (SCI-Expanded)
- XLII. **A Combined Experimental and Mathematical Approach for Molecular-based Optimization of Irinotecan Circadian Delivery**
 Ballesta A., Dulong S., Abbara C., Cohen B., Okyar A., Clairambault J., Levi F.
 PLOS COMPUTATIONAL BIOLOGY, vol.7, no.9, 2011 (SCI-Expanded)
- XLIII. **Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum**
 Okyar A., Piccolo E., Ahowesso C., Filipski E., Hossard V., Guettier C., La Sorda R., Tinari N., Iacobelli S., Levi F.
 PLOS ONE, vol.6, no.6, 2011 (SCI-Expanded)
- XLIV. **The Effect of Terpenes on Percutaneous Absorption of Tiaprofenic Acid Gel**
 Okyar A., Nuriyev M., Yildiz A., Pala-Kara Z., Ozturk N., Kaptan E.
 ARCHIVES OF PHARMACAL RESEARCH, vol.33, no.11, pp.1781-1788, 2010 (SCI-Expanded)
- XLV. **ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor**
 RAJNAI Z., Mehn D., BEERY E., Okyar A., Jani M., Toth G. K., Fueloep F., Levi F., Krajcsi P.
 DRUG METABOLISM AND DISPOSITION, vol.38, no.11, pp.2000-2006, 2010 (SCI-Expanded)
- XLVI. **Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes**
 Gungor S., Okyar A., Erturk-Toker S., Baktir G., Ozsoy Y.
 DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol.36, no.7, pp.806-813, 2010 (SCI-Expanded)
- XLVII. **Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/in vivo studies**
 Gungor S., Okyar A., Erturk-Toker S., Baktir G., Ozsoy Y.
 PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.15, no.3, pp.258-265, 2010 (SCI-Expanded)
- XLVIII. **Circadian Timing in Cancer Treatments**
 Levi F., Okyar A., Dulong S., Innominato P. F., Clairambault J.
 ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol.50, pp.377-421, 2010 (SCI-Expanded)
- XLIX. **Pre-diabetes screening program: a proactive study in Istanbul community pharmacies**
 Cakiroglu A., Koroglu A., Almila-Oztosun Z., Dundar A., Okyar A., Alp F. I., Baktir G.
 PHARMACY WORLD & SCIENCE, vol.30, no.5, pp.717, 2008 (SCI-Expanded)
- L. **Self-management of complications in diabetic patients: a pharmaceutical care program in community pharmacies**
 Koroglu A., Cakiroglu A., Almila-Oztosun Z., Dundar A., Alp F. I., Okyar A., Baktir G.
 PHARMACY WORLD & SCIENCE, vol.30, no.5, pp.657, 2008 (SCI-Expanded)
- LI. **Effectiveness of Aloe vera versus glibenclamide on serum lipid parameters, heart and skin lipid peroxidation in type-II diabetic rats**
 Ozsoy N., Yanardag R., Can A., Akev N., Okyar A.
 ASIAN JOURNAL OF CHEMISTRY, vol.20, no.4, pp.2679-2689, 2008 (SCI-Expanded)
- LII. **Effectiveness of Aloe vera versus Glibenclamide on serum lipid parameters, heart and skin lipid peroxidation in type-II diabetic rats**

- Ozsoy N., Yanardağ R., Can A., Akev N., Okyar A.
 ASIAN JOURNAL OF CHEMISTRY, vol.20, no.4, pp.2679-2689, 2008 (SCI-Expanded)
- LIII. **Effectiveness of Aloe vera versus glibenclamide on serum lipid parameters, heart and skin lipid peroxidation in type-II diabetic rats.**
 Özsoy N., Yanardağ R., Can A., Akev N., Okyar A.
 Asian Journal Of Chemistry, vol.20, pp.2679-2689, 2008 (SCI-Expanded)
- LIV. **In Vitro and Ex Vivo permeation studies of etodolac from hydrophilic gels and effect of Terpenes as enhancers**
 Taş C., Özkan Y., Okyar A., Savaşer A.
 DRUG DELIVERY, vol.14, no.7, pp.453-459, 2007 (SCI-Expanded)
- LV. **Nasal administration of heparin-loaded microspheres based on poly(lactic acid)**
 Yıldız A., Okyar A., Baktir G., Araman A., Özsoy Y.
 Farmaco, vol.60, pp.919-924, 2005 (SCI-Expanded)
- LVI. **Effect of aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models**
 Can A., Akev N., Ozsoy N., Bolkent S., Arda B. P., Yanardag R., Okyar A.
 BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol.27, no.5, pp.694-698, 2004 (SCI-Expanded)
- LVII. **Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-?? diabetic rat models.**
 Bolkent S., Akev N., Ozsoy N., Sengezer İnceli M., Can A., Okyar A., YANARDAĞ R.
 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol.42, pp.48-52, 2004 (SCI-Expanded)
- LVIII. **Effect of Aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models.**
 Can A., Akev N., Özsoy N., Bolkent Ş., Arda_Pirinççi P., Yanardağ R., Okyar A.
 BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol.27, pp.694-698, 2004 (SCI-Expanded)
- LIX. **Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models.**
 Bolkent Ş., Akev N., ÖZSOY N., Şengezer-İnceli M., Can A., Okyar A., Yanardağ R.
 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol.42, pp.48-52, 2004 (SCI-Expanded)
- LX. **Effect of Aloe vera (L.) Burm.fil. leaf gel and pulp extracts on the kidney in type-II diabetic rat models: A histological and biochemical study**
 BOLKENT Ş., AKEV N., ÖZSOY N., Şengezer-İnceli M., CAN A., OKYAR A., YANARDAĞ R.
 INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol.42, pp.48-52, 2004 (SCI-Expanded)
- LXI. **Drug-drug interactions with P-glycoprotein substrates: Mechanism for talinolol AUC increase different for p.o. and i.v. vinblastine coadministration?**
 Okyar A., Hanafy A., Baktir G., Spahn-Langguth H.
 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, vol.363, no.4, 2001 (SCI-Expanded)
- LXII. **Effect of Aloe vera leaves on blood glucose level in type I and type II diabetic rat models**
 Okyar A., Can A., Akev N., BAKTIR G., Sutlupinar N.
 PHYTOTHERAPY RESEARCH, vol.15, no.2, pp.157-161, 2001 (SCI-Expanded)
- LXIII. **P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound**
 Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., Hanafy A., Langguth P.
 INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol.36, no.1, pp.16-24, 1998 (SCI-Expanded)
- LXIV. **Synthesis of new 2-arylidene-2H-1,4-benzoxazin-3(4H)-ones**
 GEZGINCI H., SALMAN S., Okyar A., BAKTIR G.
 FARMACO, vol.52, no.4, pp.255-256, 1997 (SCI-Expanded)

Articles Published in Other Journals

- I. **A new validated high-performance liquid chromatography method for the determination of regorafenib in rat plasma: Application for pharmacokinetic study**
 AYDOĞMUŞ Z., Yılmaz E. M., ÖZTÜRK SEYHAN N., OKYAR A.

SEPARATION SCIENCE PLUS, vol.7, no.6, 2024 (ESCI)

- II. **Evaluation of the Immunomodulatory Effects of C-Vx on the Innate and Adaptive "Immune" System: Preliminary Results**
Öktelik F. B., Öztürk Civelek D., Okyar A., Çetin E., Küçüksezer U. C., Akdeniz N., Solakoğlu S., Çevik A., Öncül M. O., Deniz G.
JOURNAL OF COMPLEMENTARY MEDICINE RESEARCH, vol.13, no.3, pp.135-144, 2022 (ESCI)
- III. **The Association of ABCC5 and ABCC11 Polymorphisms with The Pharmacokinetics of 5-FU in Advanced Gastric Cancer Patients**
Kara Z., Oztas E., ÖZTÜRK D., Akyel Y. K., Turna H., Okyar A., Ozhan G.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, vol.10, no.3, pp.285-291, 2020 (ESCI)
- IV. **Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients**
Yuksel M. K., ÖZTÜRK D., Oztas E., Ozhan G., Turker A. A., KORKMAZ T., Okyar A., Kara Z. P.
ISTANBUL JOURNAL OF PHARMACY, vol.49, no.2, pp.64-69, 2019 (ESCI)
- V. **Türkiye denizlerinde zehirli denizanaları ve toksik etkileri (Venomous jellyfishes in the Turkish seas and their toxic effects).**
İŞİNİBİLİR OKYAR M., OKYAR A., ÖZTÜRK N.
Turkish Journal of Aquatic Sciences, vol.32, no.3, pp.154-169, 2017 (Peer-Reviewed Journal)
- VI. **ABC transporters: circadian rhythms and sexrelated differences**
Kara Z. P., ÖZTÜRK N., Ozturk D., OKYAR A.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, vol.3, no.1, pp.1-13, 2013 (ESCI)
- VII. **Nasal administration of ciprofloxacin loaded chitosan microspheres: in vitro and in vivo evaluation**
Gürcan D., OKYAR A., Karakoç B., Gerçeker A., Bakır G., ÖZSOY Y.
Acta Pharmaceutica Scientia, vol.52, pp.5-18, 2010 (Scopus)
- VIII. **Effect of terpenes as penetration enhancers on percutaneous penetration of tiaprofenic acid through pig skin.**
Yıldız Peköz A., Okyar A., Bakır G., Özsoy Y.
ACTA PHARMACEUTICA SCIENTIA, vol.50, no.3, pp.247, 2008 (Scopus)
- IX. **The effect of cetirizine on psychomotor performance in healthy volunteers**
OKYAR A., Bakır G.
J Fac Pharm Istanbul (İstanbul Ecz Fak Mec), vol.50, no.3, pp.247-0, 2006 (Peer-Reviewed Journal)
- X. **Immunohistochemical studies on the effect of Aloe vera on the pancreatic beta-cells in neonatal streptozotocin-induced type-II diabetic rats**
Bolkent Ş., Akev N., Can A., Bolkent H. S., Yanardağ R., Okyar A.
Egyptian Journal of Biology, vol.7, pp.14-19, 2005 (Peer-Reviewed Journal)
- XI. **Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models**
BOLKENT Ş., AKEV N., ÖZSOY N., Şengezer-Inceli M., Can A., OKYAR A., YANARDAĞ R.
Indian Journal of Experimental Biology, vol.42, no.1, pp.48-52, 2004 (Scopus)
- XII. **The effect of Aloe vera (L.) Burm. fil. on the antioxidant system in lenses of type-II diabetic rats.**
Özsoy N., Yanardağ R., Can A., Akev N., Okyar A.
İstanbul Eczacılık Fakültesi Mecmuası, vol.36, pp.83-88, 2003 (Peer-Reviewed Journal)
- XIII. **The effect of Aloe vera (L) Burm. Fil. on the antioxidant system in lenses of type-II diabetic rats**
Ozsoy N., YANARDAĞ R., Can A., Akev N., Okyar A.
Journal of Faculty of Pharmacy of Istanbul, vol.35-36, pp.83-88, 2002 (Peer-Reviewed Journal)
- XIV. **Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler).**
OKYAR A., CAN A., AKEV N., Bakır G., SÜTLÜPİNAR N.
XIII. Bitkisel İlaç Hammaddeleri Toplantısı, Bildiri Kitabı, Marmara Üniv. Yayın No. 670, Ecz. Fak. Yayın No, vol.1, pp.281-286, 2001 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Novel formulation approaches for topical and transdermal delivery of non-steroidal antiinflammatory drugs**
OKYAR A., ERGİNER Y., GÜNGÖR S.
in: Rheumatoid Arthritis– Treatment, Lemmey A., Editor, Intech, Rijeka, pp.25-48, 2011
- II. **Circadian clock control of cell cycle pathways: relevance for cancer chronotherapeutics.**
OKYAR A., Levi F.
in: Trends in Cell Cycle Research, Kenishi Yoshida, Editor, Research Signpost, Kerala-Hindistan., Kerala, pp.293-317, 2008

Refereed Congress / Symposium Publications in Proceedings

- I. **M47 Molekülünün Sıçanda Maksimum Tolere Edilebilir Dozunun (MTD) Araştırılması**
İyigün B., Taşkın A. C., Öztürk Civelek D., Çevik A., Kaptan E., Kavaklı İ. H., Okyar A.
5.Ulusal Laboratuvar Hayvanları Bilimi Kongresi, İstanbul, Turkey, 14 - 16 September 2023, pp.189-190
- II. **Effect of CLK8 on rhythmic transcriptome and replicative senescence in MRC-5 cells and further in vivo analysis**
Gül Ş., Okyar A., Kavaklı I. H.
11th International Drug Chemistry Conference, Antalya, Turkey, 9 - 12 March 2023
- III. **Hidroksiklorokin'in P-glikoprotein substratı talinlolün farmakokinetiğine etkisi**
Sakbani S., Öztürk Civelek D., Okyar A., Pala Kara Z.
26. Ulusal, 1. Uluslararası Farmakoloji Kongresi, Ankara, Turkey, 4 - 06 November 2021
- IV. **Dosing-time dependent pharmacokinetics of capecitabine and its metabolites in male mice**
Akyel Y. K., Öztürk Civelek D., Öztürk Seyhan N., Gazioglu I., Pala Kara Z., Kavaklı İ. H., Okyar A.
26. Ulusal, 1. Uluslararası Farmakoloji Kongresi, Ankara, Turkey, 04 November 2021
- V. **Dosing-time and cryptochrome dependent changes in oxaliplatin tolerability and pharmacokinetics**
Öztürk Seyhan N., Akyel Y. K., Gül Ş., Çelik M., Taşkın A. C., Sancar A., Kavaklı İ. H., Okyar A.
26th National and 1st International Pharmacology Congress, 10th Clinical Pharmacology Symposium, 9th Clinical Toxicology Symposium, İstanbul, Turkey, 4 - 06 November 2021, pp.280-281
- VI. **Dosing-Time Dependent Pharmacokinetics of Capecitabine and Its Metabolites in Male Mice.**
Akyel Y. K., Öztürk Civelek D., Öztürk Seyhan N., Gazioglu I., Pala Kara Z., Kavaklı İ. H., Okyar A.
26th National and 1st International Pharmacology Congress, 10th Clinical Pharmacology Symposium, 9th Clinical Toxicology Symposium, İstanbul, Turkey, 4 - 06 November 2021, pp.278
- VII. **mTOR İnhibitörü Everolimusun Yaşa Bağlı Farmakokinetiği**
ÖZTÜRK F., AKYEL Y. K., ÖZTÜRK D., ÖZTÜRK N., PALA KARA Z., OKYAR A.
25. Ulusal Farmakoloji Kongresi, İzmir, Turkey, 3 - 07 November 2019
- VIII. **Circadian and sex-dependent pharmacokinetics of everolimus and implications of chronotherapy**
Ozturk D., ÖZTÜRK N., Akyel Y. K., PALA KARA Z., OKYAR A.
XVI Congress of the European Biological Rhythms Society, Lyon, France, 25 - 29 August 2019, pp.100
- IX. **Circadian control of P-glycoprotein in Hepa1-6 hepatocarcinoma tumor cells and Hepa1-6 tumor-bearing mice.**
ÖZTÜRK N., Dulong S., Li X., Levi F., OKYAR A.
18th World Congress of Basic and Clinical pharmacology (WCP2018), Kyoto, Japan, 1 - 06 July 2018, pp.19
- X. **İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji Anabilim Dalı'nın Hasta Odaklı Lisans Eğitim Programı.**
ALP YILDIRIM F. İ., OKYAR A., TOPAL TANYILMAZ G., KALELİ DURMAN D., PALA KARA Z., ÇARÇAK YILMAZ N., ÖZTÜRK N., ÖZEN G., CİVELEK E., KARATAŞ KOÇBERBER E., et al.
II. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Eskişehir, Turkey, 10 - 11 May 2018, pp.24
- XI. **İstanbul Üniversitesi Eczacılık Fakültesi Farmakoloji Anabilim Dalı'nın yürüttüğü hasta odaklı**

eğitimin öğrenci geri bildirimleri ile değerlendirilmesi.

TOPAL TANYILMAZ G., ÖZTÜRK N., ÖZEN G., CİVELEK E., KARATAŞ KOÇBERBER E., ÇARÇAK YILMAZ N., KALELİ DURMAN D., PALA KARA Z., ALP YILDIRIM F. İ., OKYAR A., et al.

II. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Eskişehir, Turkey, 10 - 11 May 2018, pp.23

- XII. **Relationship between everolimus chronotoxicity and rhythms of P-glycoprotein expression in Mdr1a::Luc mice.**
ÖZTÜRK N., Li X., Giacchetti S., Levi F., OKYAR A.
International Meeting on Education & Research in Health Sciences 2017 (IMER-HS 2017), İstanbul, Turkey, 3 - 05 November 2017, pp.19
- XIII. **Fare Per2::Luc Hepa1-6 hepatokarsinoma hücre kültürlerinde sirkadiyan Per2 gen ekspresyon profilinin hücre konfluens oranına göre değişimi**
ÖZTÜRK N., Levi F., OKYAR A.
24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 - 21 October 2017, pp.24
- XIV. **mTOR inhibitörü everolimusun sirkadiyan saat sistemi üzerine etkisi ve farelerdeki kronotoksitesi**
ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÖZSOY N., ÇINAR S., DENİZ G., OKYAR A.
24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 October - 21 September 2017, pp.10
- XV. **Astım ve KOAH tedavisinde akılcı ilaç kullanımı ve eczacının rolü.**
ÖZTÜRK N., Akyel Y. K., Ekşi E. Ş., UYDEŞ DOĞAN B. S., OKYAR A.
24. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 17 - 21 October 2017, pp.12
- XVI. **Effect of everolimus on circadian rhythms of rest-activity and liver Per2 gene expression in freely moving mice.**
ÖZTÜRK N., OKYAR A.
2nd International Gazi Pharma Symposium Series (GPSS-2017), Ankara, Turkey, 11 - 13 October 2017, pp.12
- XVII. **Effect of cell confluency on Per2 gene expression oscillatory profiles in synchronized mouse Per2::luc Hepa1-6 hepatocarcinoma cell cultures.**
ÖZTÜRK N., OKYAR A.
2nd International Gazi Pharma Symposium Series (GPSS-2017), Ankara, Turkey, 11 - 13 October 2017, pp.10
- XVIII. **Relevance of dosing time for everolimus toxicity on thyroid gland and hormones in mice.**
Öztürk D., ÖZTÜRK N., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÖZSOY N., OKYAR A.
19th International Conference on Biomedicine and Medical Pharmacology (ICBMP 2017), Lizbon, Portugal, 17 - 18 August 2017, vol.4, no.8, pp.12
- XIX. **Relevance of dosing time for everolimus toxicity in respect to the circadian P-glycoprotein expression in Mdr1a::Luc mice.**
ÖZTÜRK N., Li X., Giacchetti S., Lévi F., OKYAR A.
19th International Conference on Biomedicine and Medical Pharmacology (ICBMP 2017), Lizbon, Portugal, 17 - 18 August 2017, vol.4, no.8, pp.10
- XX. **Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation**
Giacchetti S., Li X. M., Ozturk N., Cuvier C., Machowiak J., Arrondeau J., Chang-Marchand Y., Espie M., Okyar A., Levi F.
San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2016, vol.77
- XXI. **Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation.**
Giacchetti S., Li X., ÖZTÜRK N., Cuvier C., Machowiak J., Arrondeau J., Chang-Marchand Y., Espié M., OKYAR A., Lévi F.
San Antonio Breast Cancer Symposium 2016 (SABCS 2016), Teksas, United States Of America, 6 - 10 December 2016, vol.77, no.4, pp.10
- XXII. **Relevance of everolimus dosing time and for toxicity and circadian clock effects in mice.**
Li X., ÖZTÜRK N., Doan T., OKYAR A., Finkenstadt Rand B., Giacchetti S., Levi F.
7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 - 30 June 2016, pp.195
- XXIII. **The circadian timing system as a toxicity target of the anticancer mTOR inhibitor everolimus in mice.**
ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÇINAR S., DENİZ G., Li X., Giacchetti S., Levi F., et

al.

7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 June - 30 July 2016, pp.196

XXIV. Circadian control of drug metabolism, detoxification and pharmacokinetics.

OKYAR A.

7. Avrupa Farmakoloji Kongresi (EPHAR-2016), İstanbul, Turkey, 26 - 30 June 2016, pp.194

XXV. P-glycoprotein mediated pharmacokinetic interaction between talinolol and barnidipine.

ÖZTÜRK N., Öztürk D., PALA KARA Z., OKYAR A.

7. Avrupa Farmakoloji Kongresi (EPHAR 2016 – 7th European Congress of Pharmacology), İstanbul, Turkey, 26 - 30 June 2016, pp.471

XXVI. Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice.

ÖZTÜRK N., Öztürk D., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., Li X., Levi F., OKYAR A.

Society for Research of Biological Rhythms 2016 (SRBR 2016), Florida, Palm Harbor, United States Of America, 21 - 25 May 2016, pp.208

XXVII. Chronotoxicity of Everolimus on the Immune System.

Öztürk D., ÖZTÜRK N., PALA KARA Z., KAPTAN E., SANCAR BAŞ S., ÇINAR S., DENİZ G., Li X., Levi F., OKYAR A.

Society for Research of Biological Rhythms 2016 (SRBR 2016), Florida, Palm Harbor, United States Of America, 21 - 25 May 2016, pp.172-173

XXVIII. Eczacılık Eğitiminde Kalitenin Geliştirilmesi ve Sürdürülmesinde Öğrenci ile Etkileşimin Önemi

PALA KARA Z., OKYAR A., TOPAL TANYILMAZ G., ALP YILDIRIM F. İ., KALELİ DURMAN D., ÇARÇAK YILMAZ N., ÖZTÜRK N., UYDEŞ DOĞAN B. S.

1. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Ankara, Turkey, 9 - 10 May 2016, pp.47

XXIX. İstanbul Üniversitesi Eczacılık Fakültesi'nde Klinik Eczacılık Uygulamaları

PALA KARA Z., ALP YILDIRIM F. İ., KALELİ DURMAN D., ÇARÇAK YILMAZ N., ÖZTÜRK N., OKYAR A., TOPAL TANYILMAZ G., UYDEŞ DOĞAN B. S.

1. Ulusal Eczacılık Eğitimi ve Akreditasyon Kongresi, Ankara, Turkey, 9 - 10 May 2016, pp.36

XXX. Hepatokarsinoma hücre kültüründe P-glikoproteinin sirkadiyan kontrolü

ÖZTÜRK N., Dulong S., Roche V., Li X., OKYAR A., Levi F.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.206-207

XXXI. P-GLİKOPROTEİN SUBSTRATI TALİNOLOLÜN DİŞİ VE ERKEK FARELERDEKİ FARMAKOKİNETİĞİ

Öztürk D., Pala Kara Z., OKYAR A.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.388

XXXII. Hayvan Deneylelerinde Farmakolojik Prensipler

OKYAR A.

23. Ulusal Farmakoloji Kongresi, Ankara, Turkey, 7 - 10 September 2015, pp.65-67

XXXIII. Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.

Pilanci K. N., Sağlam S., Okyar A., Yucel S., Kara Z. P., Ordu C., Namal E., Ciftci R., Koksall U., Sağlam E. K.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

XXXIV. Circadian control of P-glycoprotein in hepatocarcinoma cell cultures (Hepa1-6).

ÖZTÜRK N., Li X., OKYAR A., Levi F.

Congrès de la Société Francophone de Chronobiologie, Paris, France, 29 - 31 October 2014, pp.50

XXXV. Drug Transporters: Circadian rhythms and therapeutic implications.

OKYAR A.

International Meeting on Pharmacy and Pharmaceutical Science, İstanbul, Turkey, 18 - 21 September 2014, pp.46

XXXVI. The circadian timing system as a toxicity target of the anticancer mTOR inhibitor everolimus in mice

ÖZTÜRK N., OKYAR A., Li X., Levi F.

17th World Congress of Basic and Clinical Pharmacology (WCP2014), Cape Town, South Africa, 13 - 18 July 2014, vol.115, no.1, pp.318

- XXXVII. **Transmucosal delivery of dimenhydrinate to rabbits employing mucoadhesive patch.**
YILDIZ PEKÖZ A., OKYAR A., OCAK DEMİRCİ E. M., KAPTAN E., TEKELİ F., ERDAL M. S., SAĞIRLI A. O.
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology,, Lizbon, Portugal, 31
March - 03 April 2014, pp.269-270
- XXXVIII. **P-glikoprotein in tümördeki ritimlerinin in vitro incelenmesi.**
ÖZTÜRK N., OKYAR A., Van Der Horst B., Levi F.
22. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 4 - 07 November 2013, pp.195
- XXXIX. **P-glikoprotein substratı talinololün faredeki kronofarmakokinetiği.**
PALA KARA Z., ÖZTÜRK N., Filipski E., Orman M., Levi F., OKYAR A.
22. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 4 - 07 November 2013, pp.88
- XL. **Circadian and sex-dependent rhythms in P-glycoprotein expression and function in mice**
OKYAR A., Filipski E., Piccolo E., ÖZTÜRK N., PALA KARA Z., Levi F.
XIII Congress of the European Biological Rhythms Society, Münih, Germany, 18 - 22 August 2013, pp.139-140
- XLI. **Effect of Amaranthus lividus against carbon tetrachloride-induced kidney damage in rats**
YILMAZ ÖZDEN T., CAN A., PALA KARA Z., OKYAR A.
19th International Symposium on Microsomes and Drug Oxidations-12th European Regional ISSX Meeting,
Noordwijk Aan Zee, Netherlands, 17 - 21 June 2012, pp.139
- XLII. **Barnidipin ve talinolol arasındaki P-glikoproteine bağlı olası bir farmakokinetik etkileşiminin incelenmesi**
ÖZTÜRK N., PALA KARA Z., OKYAR A.
21. Ulusal Farmakoloji Kongresi (Türk Farmakoloji Derneği), Eskişehir, Turkey, 19 - 22 October 2011, pp.407
- XLIII. **The assessment of the work in the last three years of Istanbul University Local Ethical Committee for Animal Experiments**
Kaymaz F. A., Yalıtık M., Dikmen Tekeli F., Yamantürk Çelik A. P., Belce A., Armutak A., Okyar A., Olgun B., Demir S.
3rd East Mediterranean International Council for Laboratory Animal Science (ICLAS) Symposium & XV. General
Assembly, İstanbul, Turkey, 10 - 12 June 2011, pp.126
- XLIV. **Protective activity of Amaranthus lividus L. against acute hepatotoxicity in rats**
Ozden T. Y., Kara Z. P., Okyar A., Can A.
36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.320
- XLV. **Hepatoprotective effect of Smilax excelsa L.**
ÖZSOY N., OKYAR A., CAN A., AKEV N., Baktır G.
The 2nd International Symposium on Medicinal Plants, Their Cultivation and Aspects of Uses, Jordan, 1 - 04
November 2010, pp.36-37
- XLVI. **Effect of Smilax excelsa L. on the antioxidant system in kidney tissue**
ÖZSOY N., OKYAR A., AKEV N., CAN A., Baktır G.
The 2nd International Symposium on Medicinal Plants, Their Cultivation and Aspects of Uses, Jordan, 1 - 04
November 2010, pp.37-38
- XLVII. **Effect of Smilax excelsa L. leaf extract on liver injury in rats**
ÖZSOY N., ARDA_PİRİNÇÇİ P., OKYAR A., BOLKENT Ş., AKEV N., Baktır G., CAN A., Arda-Pirinççi P.
The 17th IFSM International Microscopy Congress (IMC 17), Brazil, 1 - 04 September 2010, pp.0-24
- XLVIII. **Vers l'optimisation de l'administration d'un agent anticancereux: etude experimentale et mathematique de la pharmacocinetique-pharmacodynamie de l'Irinotecan et de son controle par l'horloge circadienne**
Ballesta A., Dulong S., OKYAR A., Levi F.
42. Fransızca Konuşulan Ülkeler Kronobiyoloji Derneği Kongresi, France, 1 - 04 September 2010, pp.38
- XLIX. **Morphological and biochemical investigations of Amaranthus lividus L. in CCl4-induced liver injury rat models**
YILMAZ ÖZDEN T., CAN A., SANCAR BAŞ S., PALA KARA Z., OKYAR A., BOLKENT Ş.
IMC17, The 17th IFSM International Microscopy Congress, Brazil, 1 - 04 September 2010, pp.0-25
- L. **Circadian changes in abcc2 expression in mouse ileum.**
OKYAR A., Ahowesso C., Filipski E., Piccolo E., Tinari N., Iacobelli S., Levi F.

42. Fransızca Konuşulan Ülkeler Kronobiyoloji Derneği Kongresi, France, 1 - 04 September 2010, pp.39

- L.I. **The CDK inhibitor roscovitine (Seliciclib) is a selective substrate of human P-glycoprotein (P-gp/ABCB1/MDR1)**
Rajnai Z., Mehn D., Beery E., Okyar A., Jani M., Fulop F., Levi F., Krajcsi P.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.299-300
- L.II. **Antioxidant Effect of Amaranthus lividus L. Against CCl4-induced Hepatotoxicity in Rats**
Yilmaz T., Can A., Pala Z., Okyar A.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.242-243
- L.III. **The effect of terpenes on skin absorption of tiaprofenic acid gel ex vivo and in vivo in rats**
PALA KARA Z., Nuriyev M., YILDIZ PEKÖZ A., ÖZTÜRK N., OKYAR A.
16. IUPHAR Dünya Farmakoloji Kongresi (International Union of Pharmacology, 16th World Congress on Basic and Clinical Pharmacology 2010), Kopenhag, Denmark, 17 - 23 July 2010, pp.210
- L.IV. **Preclinical model for the personalization of cancer chronotherapeutics.**
Ahowesso C., Li X., Dulong S., Filipski E., OKYAR A., Levi F.
XI. Avrupa Biyolojik Ritimler Derneği Kongresi, France, 1 - 04 August 2009, pp.209
- L.V. **Rhythmic intestinal drug elimination via ABC transporters: a potential determination of anticancer drug chronopharmacology**
OKYAR A., Filipski E., Ahowesso C., Dulong S., Levi F.
XI. Avrupa Biyolojik Ritimler Derneği Kongresi, France, 1 - 04 August 2009, pp.153
- L.VI. **Rhythmic intestinal drug elimination via ABC transporters: a potential determination of anticancer drug chronopharmacology**
OKYAR A., Filipski E., Ahowesso C., Levi F., Dulong S., Delaunay F.
PROUST (The Temporal Dimension of Functional Dynamics; Genes at work on time, Italy, 1 - 04 October 2008, pp.37
- L.VII. **Effect of terpenes as penetration enhancers on percutaneous penetration of tiaprofenic acid through pig skin**
OKYAR A., YILDIZ PEKÖZ A., AKSU B., OZSOY Y., Baktr G.
6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Barselona, Spain, 7 - 10 April 2008, pp.11-12
- L.VIII. **Circadian changes in intestinal secretion: Drug-drug interactions with the P-glycoprotein (P-gp) substrate talinolol**
Okyar A., Baktir G., Spahn-Langguth H.
49th Annual Meeting of the German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology, Mainz, Germany, 11 - 13 March 2008, vol.377, pp.62
- L.IX. **Prediabetes screening program: A Proactive study in İstanbul community pharmacies**
Cakiroglu ., Koroglu A., Öztosun Z., Dundar ., OKYAR A., ALP YILDIRIM F. İ., Baktr G.
ESCP (European Society of Clinical Pharmacy) 36th European Symposium on Clinical Pharmacy, İstanbul, Turkey, 25 - 27 October 2007, pp.1
- L.X. **Self management of complications in diabetic patients: a pharmaceutical care program in community pharmacies**
Koroglu A., Cakiroglu ., Öztosun Z., Dundar ., ALP F. İ., OKYAR A., Baktr G.
ESCP (European Society of Clinical Pharmacy) 36th European Symposium on Clinical Pharmacy, İstanbul, Turkey, 25 - 27 October 2007, pp.10
- L.XI. **P-glikoprotein (P-gp) substratları arasındaki ilaç-ilaç etkileşimleri: P-gp'ye bağımlı intestinal sekresyondaki gece-gündüz farklılığının talinololün farmakokinetiğine etkisi**
OKYAR A.
19. Ulusal Farmakoloji Kongresi, Trabzon, Turkey, 1 - 04 October 2007, pp.12
- L.XII. **Pre-diabetes screening program: A proactive study in Istanbul community pharmacies**
Çakiroğlu A., Köroğlu A., Öztosun Z., Dünder A., OKYAR A., Alp İ., Baktr G.

36th European Symposium on Clinical Pharmacy, Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience, Turkey, 1 - 04 October 2007, pp.10

- LXIII. **Self-management of complications in diabetic patients: a pharmaceutical care program in community pharmacies.**
Koroğlu A., Çakıroğlu A., Öztosun Z., Dünder A., OKYAR A., Alp İ., Baktır G.
36th European Symposium on Clinical Pharmacy, Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience, Turkey, 1 - 04 October 2007, pp.10
- LXIV. **in vitro and in vivo studies on ondansetron HCl loaded biodegradable microspheres**
ERGİNER Y., GÜNGÖR S., OKYAR A., TOKER S., Baktır G.
Pharmaceutical Sciences World Congress, Amsterdam, Netherlands, 22 - 25 April 2007, pp.1
- LXV. **Vücutta Parçalanabilen Heparin Mikrokürelerinin Nazal Yol ile Uygulanması**
ERGİNER Y., YILDIZ PEKÖZ A., OKYAR A., Baktır G., ARAMAN A. O.
VI. Ulusal Tromboz, Hemostaz ve Anjiyolojik Kongresi, İzmir, Turkey, 5 - 07 May 2006, pp.1
- LXVI. **Deneysel diabette Aloe vera'nın pankreas dokusu üzerine etkisi**
AKEV N., CAN A., BOLKENT H. S., BOLKENT Ş., YANARDAĞ R., OKYAR A.
XVIII. Ulusal Kimya Kongresi, Kars, Turkey, 1 - 04 July 2004, pp.513
- LXVII. **Deneysel diabette Aloe vera'nın lipid profili üzerine etkisi**
CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.
XVIII. Ulusal Kimya Kongresi, Kars, Turkey, 1 - 04 July 2004, pp.514
- LXVIII. **In vitro and In vivo Evaluation of Ciprofloxacin HCl Loaded Chitosan Microspheres by Spray-Drying Method and In Vivo Evaluation for Nasal Administration**
ERGİNER Y., GÜRCAN D., OKYAR A., KARAKOÇ B., BAKTIR G., GERÇEKER A.
European Conference on Drug Delivery and Pharmaceutical Technology, Sevilla, Spain, 10 - 12 May 2004, pp.1
- LXIX. **Circadian variation in effective permeabilities of talinolol and losartan in rats: Metabolism- or transport-related?**
Lemmer B., Dressler C., Okyar A., Baktır G., Spahn-Langguth H.
45th Spring Meeting of the German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology, Mainz, Germany, 9 - 11 March 2004, vol.369
- LXX. **Biodegradable heparin microspheres: II. Nasal administration of heparin microspheres**
ERGİNER Y., YILDIZ PEKÖZ A., OKYAR A., ARAMAN A. O., BAKTIR G.
5th International Conference and Workshop on Cell Culture and In-vitro models for Drug Absorption and Delivery, Saarbrücken, Germany, 25 February - 05 March 2004, pp.1
- LXXI. **Circadian variation of effective permeabilities of talinolol and losartan in rats. Metabolism -or transport- related?**
OKYAR A., Dressler C., Hanafy A., Baktır G., Lemmer B., Spahn-Langguth H.
XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.197
- LXXII. **Effect of Aloe vera leaf gel and pulp extracts on serum lipid parameters and heart tissue lipid peroxidation in type-II diabetic rats**
CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.
3 rd International Symposium on Natural Drugs Proceedings, Italy, 1 - 04 October 2003, pp.17-19
- LXXIII. **Effect of P-glycoprotein inhibitor atorvastatin on absorption and distribution of talinolol**
OKYAR A., PALA KARA Z., Spahn-Langguth H., Baktır G.
XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.88
- LXXIV. **Effect of simvastatin on talinolol pharmacokinetics**
PALA KARA Z., OKYAR A., Spahn-Langguth H., Baktır G.
XVII. Ulusal Farmakoloji Kongresi, 1. Klinik Farmakoloji Sempozyumu ve Türk-Hollanda Farmakoloji Dernekleri Ortak Toplantısı, Antalya, Turkey, 1 - 04 October 2003, pp.92
- LXXV. **Effect of Aloe vera on skin lipid peroxidation in type-II diabetic rats**
AKEV N., ÖZSOY N., CAN A., YANARDAĞ R., OKYAR A.

3 rd International Symposium on Natural Drugs Proceedings, Italy, 1 - 04 October 2003, pp.17-19

- LXXXVI. **The effect of Aloe vera (L.) Burm. fil. on the antioxidant system in lenses of type-II diabetic rats**
ÖZSOY N., YANARDAĞ R., CAN A., AKEV N., OKYAR A.
1 st International Congress on the Chemistry of Natural Products (ICNP), TRABZON, Turkey, 1 - 04 October 2002, pp.0-66
- LXXXVII. **The effect of Aloe vera (L.) Burm Fil., on the antioxidant system in lenses of type-II diabetic rats**
Ozsoy N., YANARDAĞ R., Can A., Akev N., Okyar A.
Proceedings of ICNP-2002, Trabzon, Turkey, 1 - 04 October 2002, pp.263-266
- LXXXVIII. **The effect of Aloe vera (L.) Burm. Fil. leaf gel and pulp extracts on the kidney in type-II diabetic rat models: A histological and biochemical study**
Bolkent Ş., Akev N., Özsoy N., Şengezer İnceli M., Can A., Okyar A., YANARDAĞ R.
VIth Plant Life of Southwest Asia Symposium, Turkey, 1 - 04 June 2002, pp.48
- LXXXIX. **The effect of Aloe vera (L.) Burm. fil leaf gel and pulp extracts on the liver in type-II diabetic rat models:a biochemical study.**
CAN A., AKEV N., ÖZSOY N., YANARDAĞ R., OKYAR A.
VIth Plant Life of Southwest Asia Symposium, Turkey, 1 - 04 June 2002, pp.50
- LXXX. **The effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on the kidney in type-II diabetic rat models: A histological and biochemical study**
BOLKENT Ş., AKEV N., ÖZSOY N., İNCELİ M., CAN A., OKYAR A., YANARDAĞ R.
VI th Plant Life of Southwest Asia Symposium, Yüzüncü Yıl University, VAN, Turkey, 1 - 04 June 2002, pp.48
- LXXXI. **Drug-drug interactions with P-glycoprotein substrates: Mechanism for AUC increase is different for p.o. and i.v. vinblastine coadministration?**
OKYAR A., Hanafy A., Baktır G., Spahn-Langguth H.
Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 42. Spring Meeting, Germany, 1 - 04 March 2001, pp.0-115
- LXXXII. **Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler)**
OKYAR A., AKEV N., CAN A., Baktır G., SÜTLÜPİNAR N.
XIII. Bitkisel İlaç Hammaddeleri Toplantısı, Bildiri Kitabı, Marmara Üniv. Yayın No. 670, Ecz. Fak. Yayın No. 17, İstanbul, Turkey, 1 - 04 January 2001, pp.281-286
- LXXXIII. **Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler)**
OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPİNAR N.
XIII. Bitkisel İlaç Hammaddeleri Toplantısı, İstanbul, Turkey, 1 - 04 September 2000, pp.0-67
- LXXXIV. **Aloe vera yapraklarının tip II diabetik sıçanların kan şekeri düzeyine etkisi (kronik deneyler).**
OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPİNAR N.
XIII. Bitkisel İlaç Hammaddeleri Toplantısı, İstanbul, Turkey, 1 - 04 September 2000, pp.67
- LXXXV. **Terfenadinin genç deneklerde psikomotor performans etkisi**
Hocaoğlu N., OKYAR A., Baktır G.
XV. Ulusal Farmakoloji Kongresi, Aydın, Turkey, 1 - 04 November 1999, pp.12-13
- LXXXVI. **Aloe vera yapraklarının tip I ve tip II diabetik sıçanların kan glukoz düzeyine etkisi.**
OKYAR A., CAN A., AKEV N., SÜTLÜPİNAR N., Baktır G.
Türk Farmakoloji Derneği XV. Ulusal Farmakoloji Kongresi, Antalya, Turkey, 1 - 04 November 1999, pp.7-4
- LXXXVII. **Effect of Aloe vera leaves on blood glucose level in type-I and type-II diabetic rat models**
OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPİNAR N.
2000 Years of Natural Products Research – Past, Present and Future, Netherlands, 1 - 04 July 1999, pp.51
- LXXXVIII. **Effect of Aloe vera leaves on blood glucose level in type-I and type-II diabetic rat models.**
OKYAR A., CAN A., AKEV N., Baktır G., SÜTLÜPİNAR N.
2000 Years of Natural Products Research - Past, Present and Future, Netherlands, 1 - 04 July 1999, pp.51
- LXXXIX. **Setirizinin psikomotor performans etkisinin psikometrik testlerle incelenmesi**
OKYAR A., Baktır G.
XIV. Ulusal Farmakoloji Kongresi ve 'Angiotensin-II Receptor Antagonists in Cardiovascular Disease' Sempozyumu, Antalya, Turkey, 1 - 04 November 1997, pp.772-777

Other Publications

- I. **ABC Taşıyıcı Proteinleri: Sirkadiyan Ritimler ve Cinsiyete Bağlı Farklılıklar**
PALA KARA Z., ÖZTÜRK N., Öztürk D., OKYAR A.
Other, pp.1-13, 2013
- II. **Kronofarmakokinetik**
PALA KARA Z., OKYAR A.
Other, pp.19-21, 2011
- III. **Biyolojik saatin moleküler mekanizmaları**
ÖZTÜRK N., OKYAR A.
Other, pp.18-20, 2010
- IV. **P-glikoprotein ve P-glikoprotein ila farmakokinetiğindeki rolü**
OKYAR A.
Other, pp.18-22, 2005

Supported Projects

- ÖZTÜRK O., ÇELİK İ., GEÇİN M. N., TAŞKIN A. C., TEMİZYÜREK A., CEVİZ A. B., ÖZTÜRK T., OKYAR A., Project Supported by Higher Education Institutions, Ksenogreft meme tümör modeli oluşturulan nude farelerde polifenolik formülasyonun PFK5120 antikanser etkinliğinin araştırılması, 2024 - Continues
- AK G., OKYAR A., Project Supported by Higher Education Institutions, İstanbul Üniversitesi AR-GE, Girişimcilik ve Yenilikçilik Sürekliliği ve Geliştirilmesi, 2023 - Continues
- ÖZTÜRK SEYHAN N., OKYAR A., GAZIOĞLU İ., ÖZTÜRK CİVELEK D., ÜNAL B., AKYEL Y. K., Project Supported by Higher Education Institutions, Resveratrolün everolimus farmakokinetiğine etkisinin sıçanlarda incelenmesi, 2022 - Continues
- Gül Ş., Topçul M. R., Çetin İ., Çalışkan M., Okyar A., TÜBİTAK Project, İla yeniden konumlandırma metoduyla biyogüvenli SARS-CoV-2 replikonu kullanılarak SARS-CoV-2 inhibitörü bulunması, 2022 - 2025
- OKYAR A., ÖZTÜRK SEYHAN N., KAVAKLI İ. H., GÜL Ş., Project Supported by Higher Education Institutions, CLK 8 Molekülünün in vivo etkilerinin incelenmesi, 2022 - 2024
- OKYAR A., İYİĞÜN B., Project Supported by Higher Education Institutions, Kriptokrom1 protein yıkımını hızlandıran m47 molekülünün sıçanda maksimum tolere edilebilir dozunun (MTD) araştırılması, 2022 - 2023
- ERGİNER Y., NAZLI H., ÖZTÜRK D., MESUT B., OKYAR A., Project Supported by Higher Education Institutions, Çözünürlüğü düşük etkin maddenin kendiliğinden emülsifiye olan yeni formülasyonlarının geliştirilmesi, in vitro ve in vivo olarak değerlendirilmesi, 2019 - 2021
- OKYAR A., KAVAKLI H., AKYEL Y. K., Project Supported by Higher Education Institutions, Kapesitabinin Faredeki Kronofarmakokinetiğinin İncelenmesi, 2018 - 2021
- ÖNCÜL M. O., OKYAR A., SARIDOĞAN E., KARA M., KORUL O., PELDEK M., ÖZDEMİR H., KAYIKCI S., KARA TIKTIKLAR H., KÖSE S., et al., Project Supported by Higher Education Institutions, İstanbul Üniversitesi Araştırma Alt Yapısı Geliştirme ve Sürekliliği desteği, 2018 - 2021
- OKYAR A., ÖZTÜRK N., KAVAKLI H., SANCAR A., ÇAL S., TAŞKIN A. C., AKYEL Y. K., Project Supported by Higher Education Institutions, Kriptokrom nakavt farelerde oksaliplatin kronofarmakokinetiğinin ve oksaliplatinin karaciğerdeki etkilerinin genom düzeyinde incelenmesi, 2017 - 2021
- Taşkın A. C., Sancar A., Kavaklı İ. H., Öztürk Seyhan N., Gül Ş., Okyar A., Akyel Y. K., Project Supported by Higher Education Institutions, Kriptokrom nakavt farelerde oksaliplatin kronofarmakokinetiğinin ve oksaliplatinin karaciğerdeki etkilerinin genom düzeyinde incelenmesi, 2017 - 2021
- YALTIRIK M., AHISHALI B., TURGUT C. T., ÖZTÜRK D., OKYAR A., GÜNGÖR S., ERGİNER Y., KOTİL T., DİRİCAN A., Project Supported by Higher Education Institutions, Vitamin D ve PRP İçeren Biyoyumlu Taşıyıcıların Sıçan Kalvaryasında Oluşturulan Kemik Defektleri Üzerine Etkilerinin Araştırılması, 2018 - 2020
- YILDIZ PEKÖZ A., ÖZTÜRK N., PALA KARA Z., AKBAL DAĞISTAN Ö., ŞAHİN G., BEKTAŞ KAYHAN K., OKYAR A., Project Supported by Higher Education Institutions, SEVİMELİN İÇEREN BİYOADHEZİF MUKOZAL DOZAJ FORMLARININ İN VİVO OLARAK KSEROSTAMİ ÜZERİNE ETKİSİNİN ARAŞTIRILMASI, 2017 - 2020

Okyar A., TUBITAK Project, Kriptokrom protein yıkımını hızlandıran moleküllerin p53 mutant farelerinde etkinliğinin incelenmesi, 2015 - 2020

OKYAR A., ÖZTÜRK N., SANCAR BAŞ S., ÖZTÜRK D., KAPTAN E., PALA KARA Z., Project Supported by Higher Education Institutions, Everolimusun sıçan karaciğerindeki kronotoksitesisi, 2017 - 2019

OKYAR A., ÖZTÜRK N., PALA KARA Z., ÖZTÜRK F., LEVİ F., ÖZTÜRK D., AKYEL Y. K., Project Supported by Higher Education Institutions, mTOR inhibitörü everolimusun yaşa bağlı farmakokinetiğinin incelenmesi, 2017 - 2019

PALA KARA Z., OKYAR A., ÖZTÜRK N., ÖZTÜRK D., Project Supported by Higher Education Institutions, P-glikoprotein protein ekspresyonunun cinsiyete ve zamana bağlı olarak C57BL/6 farelerde değerlendirilmesi, 2017 - 2019

Taşkın A. C., Öztürk Seyhan N., Okyar A., Kavaklı İ. H., Türkay M., TUBITAK Project, CRY Proteinini Yıkımını Hızlandıran Sentetik Moleküllerin Kanser Tedavisinde Kullanımı, 2016 - 2019

YILDIZ PEKÖZ A., OKYAR A., PALA KARA Z., ÖZTÜRK N., ŞAHİN G., Project Supported by Higher Education Institutions, SEVİMELİN İÇEREN BİYODHEZİF MUKOZAL DOZAJ FORMLARI: İN VİTRO DEĞERLENDİRİLMESİ VE İN VİVO OLARAK KSEROSTAMİ ÜZERİNE ETKİSİNİN ARAŞTIRILMASI, 2015 - 2018

ÖZTÜRK SEYHAN N., GIACCHETTI S., LEVİ F., OKYAR A., Project Supported by Higher Education Institutions, Relevance of Dosing Time for Everolimus Toxicity in Respect to the Circadian P-glycoprotein Expression in Mdr1a::Luc Mice, 2017 - 2017

OKYAR A., LEVİ F., ÖZTÜRK N., Project Supported by Higher Education Institutions, Everolimusun P-gp ekspresyonuna etkisinin mdr1a:FLuc farelerde incelenmesi, 2016 - 2017

ÖZTÜRK SEYHAN N., KAPTAN E., Lİ X., LÉVİ F., PALA KARA Z., ÖZTÜRK D., SANCAR BAŞ S., OKYAR A., Project Supported by Higher Education Institutions, Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice, 2016 - 2017

ÖZHAN G., ÖZTAŞ E., PALA KARA Z., OKYAR A., KARA H., ÖZTÜRK D., ARICI M., Project Supported by Higher Education Institutions, Telomeraz Ters Transkriptaz (TERT) Enzimi ve P-Glikoprotein (MDR1) Taşıyıcı Proteininin Meme Kanser Oluşumu ve İlaç (Everolimus) Direnci Üzerine Etkisinin Araştırılması, 2015 - 2017

CAN A., ALTINCIK A., KURT ŞİRİN Ö., TUNALI S., AKEV N., YANARDAĞ R., SANCAR BAŞ S., BOLKENT Ş., HASBAL G., SÖNMEZ F., et al., Project Supported by Higher Education Institutions, Vanadyum sülfatın diabetik sıçanların mide ve akciğer dokuları üzerine biokimyasal etkileri, 2015 - 2016

OKYAR A., ÖZTÜRK N., ÖZTÜRK D., Project Supported by Higher Education Institutions, Everolimusun faredeki kronotoksitesisinin hematolojik açıdan incelenmesi, 2015 - 2016

OKYAR A., Project Supported by Higher Education Institutions, Mdr1a:FLuc farelerde P-glikoproteininin barsak aktivitesinin RT-BIO ile incelenmesi, 2013 - 2015

OKYAR A., Project Supported by Higher Education Institutions, 5-Florourasil'in sıvı sıvı ekstraksiyonu yöntemi ve HPLC ile tayini, 2013 - 2014

OKYAR A., Project Supported by Higher Education Institutions, P-glikoprotein substratı talinololün dişi ve erkek farelerdeki farmakokinetiği, 2013 - 2014

OKYAR A., Project Supported by Higher Education Institutions, P-glikoprotein aktivitesindeki diurnal değişimler, 2013 - 2013

OKYAR A., Project Supported by Higher Education Institutions, Tümör taşıyan farelerde ABC taşıyıcı proteinlerinin mRNA ekspresyon ritimlerinin ve P-glikoprotein fonksiyonel aktivitesinin incelenmesi, 2010 - 2013

OKYAR A., Project Supported by Higher Education Institutions, Sirkadiyan saatler ve ilaç uygulama, 2012 - 2012

OKYAR A., Project Supported by Higher Education Institutions, Abcc2'nin barsaktaki ekspresyon ritimlerinin irinotekan kronotoksitesisine etkisi, 2011 - 2012

OKYAR A., Project Supported by Higher Education Institutions, ABC taşıyıcı proteinlerin (ABCB1) roskovitin'in farmakokinetiğine olası etkisi, 2011 - 2012

OKYAR A., Project Supported by Higher Education Institutions, Hücre siklusu inhibitörü roskovitin, saf P-glikoprotein substratı olan talinolol ile etkileşiminin in vivo incelenmesi, 2010 - 2012

OKYAR A., Project Supported by Higher Education Institutions, Hücre siklusu inhibitörü roskovitin sıçan plazmasından analitik validasyonu, 2011 - 2011

OKYAR A., Project Supported by Higher Education Institutions, Abcc2 taşıyıcı proteininin fare barsağındaki sirkadiyen ritimleri, 2010 - 2010

OKYAR A., Project Supported by Higher Education Institutions, Kanserde sirkadiyen tedavi, 2010 - 2010

OKYAR A., Project Supported by Higher Education Institutions, Barnidipin ve talinolol arasındaki P-glikoproteine bağlı

olası bir farmakokinetik etkileşmenin incelenmesi, 2009 - 2010

OKYAR A., Project Supported by Higher Education Institutions, ABC taşıyıcı proteinlerinin sirkadiyen ritimleri, 2009 - 2009

OKYAR A., Project Supported by Higher Education Institutions, Antienflamatuvar ilaçların topikal formülasyonlarının deriden penetasyonlarının incelenmesi, 2008 - 2009

OKYAR A., EU Supported Other Project, Biosimulation, a new tool for drug development, 2006 - 2009

OKYAR A., EU Framework Program Project, Temporal Genomics for Tailored Chronotherapeutics (TEMPO), 2006 - 2009

OKYAR A., Project Supported by Other Official Institutions, Ondansetronun mikrokürelerinin vücutta parçalanabilen polimerler ile hazırlanması ve nazal olarak uygulanması üzerine çalışmalar., 2001 - 2004

Activities in Scientific Journals

Journal of Faculty of Pharmacy of Istanbul University, Advisory Committee Member, 2013 - Continues

Türk Farmakoloji Derneği E-Bülteni, Publication Committee Member, 2012 - Continues

Memberships / Tasks in Scientific Organizations

İstanbul Eczacı Odası, Member, 2017 - Continues

Türk Farmakoloji Derneği, Member, 1996 - Continues

İÜ Eczacılık Fak. Mezun ve Mensupları Geliştirme Derneği, Member, 1996 - Continues

Scientific Refereeing

Journal of Drug Delivery Science and Technology, National Scientific Refreed Journal, December 2017

Cell Cycle, National Scientific Refreed Journal, June 2017

Oncotarget, SCI Journal, August 2016

TUBITAK Project, June 2016

Pharmaceutics, Other journals, January 2016

TUBITAK Project, December 2015

Mini Reviews in Medicinal Chemistry, National Scientific Refreed Journal, October 2015

TUBITAK Project, October 2015

J Pharm Pharmacol , SCI Journal, September 2015

MUSBED, National Scientific Refreed Journal, July 2015

Prostaglandins Other Lipid Mediators, SCI Journal, June 2015

MUSBED, National Scientific Refreed Journal, April 2015

Eur J Drug Metab Pharmacokinet, SCI Journal, March 2015

Expert Opin Drug Deliv, SCI Journal, January 2015

Mol Pharmaceut, SCI Journal, November 2014

Drug Design Dev Ther, SCI Journal, October 2014

MUSBED, National Scientific Refreed Journal, August 2014

Expert Opin Drug Deliv, SCI Journal, February 2014

J Pharm Pharmacol, SCI Journal, July 2013

Journal of Molecular Cell Biology, National Scientific Refreed Journal, November 2011

J Pharm Pharmacol, National Scientific Refreed Journal, October 2011

Therapeutic Delivery, Other journals, July 2011

Metrics

Publication: 173

Citation (WoS): 1565

Citation (Scopus): 1883

H-Index (WoS): 21

H-Index (Scopus): 22

Congress and Symposium Activities

Türk Farmakoloji Derneği Kongresi, Attendee, Trabzon, Turkey, 2017

7. Avrupa Farmakoloji Kongresi, Attendee, İstanbul, Turkey, 2016

Gazi Pharma Symposium Series, Attendee, Antalya, Turkey, 2015

Türk Farmakoloji Derneği Kongresi, Attendee, Ankara, Turkey, 2015

Societe Francophone de Chronobiologie (SCF Meeting), Attendee, Paris, France, 2014

4. Uluslararası Eczacılık ve Farmasötik Bilimler Kongresi, Attendee, İstanbul, Turkey, 2014

II. Ulusal Klinik Eczacılık ve Farmasötik Bakım Kongresi, Attendee, Antalya, Turkey, 2013

Türk Farmakoloji Derneği Kongresi, Attendee, Antalya, Turkey, 2013

Avrupa Biyolojik Ritimler Derneği Kongresi, Attendee, München, Germany, 2013

Societe Francophone de Chronobiologie (SCF Meeting), Attendee, Nice, Turkey, 2011

Türk Farmakoloji Derneği Kongresi, Attendee, Antalya, Turkey, 2009

Türk Farmakoloji Derneği Kongresi, Attendee, Trabzon, Turkey, 2007

Scholarships

Doktora sonrası araştırma bursu (2219), TÜBİTAK, 2007 - 2008

Kısa süreli araştırma bursu (Forschungskurzstipendium), Other International Organizations, 2000 - 2001

Non Academic Experience

Other Public Institution, Tc Sağlık Bak. Haseki Eğitim Ve Araştırma Hastanesi